{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:42:28Z","timestamp":1791859348993,"version":"4.3.4"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.phrs.2016.07.038","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T18:35:20Z","timestamp":1469644520000},"page":"784-803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":355,"special_numbering":"C","title":["Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4139","authenticated-orcid":false,"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2016.07.038_bib0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmb.2009.01.041","article-title":"Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains","volume":"387","author":"Williams","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semcdb.2008.07.020","article-title":"The JAK kinases: not just another kinase drug discovery target","volume":"19","author":"Wilks","year":"2008","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0015","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1073\/pnas.91.14.6374","article-title":"Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes","volume":"91","author":"Kawamura","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.07.038_bib0020","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.07.038_bib0025","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.phrs.2016.07.038_bib0030","series-title":"Harrison\u2fffs Principles of Internal Medicine","first-page":"2650","article-title":"Introduction to the immune system","author":"Haynes","year":"2012"},{"key":"10.1016\/j.phrs.2016.07.038_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus kinase (JAK) activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem. J."},{"issue":"17","key":"10.1016\/j.phrs.2016.07.038_bib0040","first-page":"395","article-title":"STATs: an old story yet mesmerizing","volume":"1","author":"Abroun","year":"2015","journal-title":"Cell J."},{"key":"10.1016\/j.phrs.2016.07.038_bib0045","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0092-8674(00)81443-9","article-title":"Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA","volume":"93","author":"Chen","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2016.07.038_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"409","key":"10.1016\/j.phrs.2016.07.038_bib0055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/35053086","article-title":"CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling","volume":"18","author":"Irie-Sasaki","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2016.07.038_bib0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0065","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.07.038_bib0070","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.07.038_bib0075","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1098\/rstb.2012.0054","article-title":"Evolution of the eukaryotic protein kinases as dynamic molecular switches","volume":"367","author":"Taylor","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2016.07.038_bib0080","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2016.07.038_bib0085","doi-asserted-by":"crossref","first-page":"e1001680","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0090","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","article-title":"Regulation of protein kinases; controlling activity through activation segment conformation","volume":"15","author":"Nolen","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2016.07.038_bib0095","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1021\/bi036109b","article-title":"Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state","volume":"43","author":"Chatti","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2016.07.038_bib0100","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.07.038_bib0105","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.07.038_bib0110","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.phrs.2016.03.012","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"107","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.07.038_bib0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.07.038_bib0120","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: structures and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.07.038_bib0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.07.038_bib0130","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2016.07.038_bib0135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.07.038_bib0140","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/MCB.17.5.2497","article-title":"Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop","volume":"17","author":"Feng","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0145","doi-asserted-by":"crossref","first-page":"13850","DOI":"10.1073\/pnas.94.25.13850","article-title":"Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity","volume":"94","author":"Zhou","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.07.038_bib0150","doi-asserted-by":"crossref","first-page":"20494","DOI":"10.1074\/jbc.271.34.20494","article-title":"Interferon-\u03b1-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase","volume":"271","author":"Gauzzi","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2016.07.038_bib0155","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1128\/MCB.20.10.3387-3395.2000","article-title":"Regulation of the Jak2 tyrosine kinase by its pseudokinase domain","volume":"20","author":"Saharinen","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0160","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1073\/pnas.1401180111","article-title":"Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition","volume":"111","author":"Lupardus","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.07.038_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20141293","article-title":"JAK2 activation by growth hormone and other cytokines","volume":"466","author":"Waters","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2016.07.038_bib0170","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.07.038_bib0175","first-page":"e29569","article-title":"A new mechanism for growth hormone receptor activation of JAK2, and implications for related cytokine receptors","volume":"3","author":"Waters","year":"2014","journal-title":"JAKSTAT"},{"key":"10.1016\/j.phrs.2016.07.038_bib0180","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1128\/MCB.01589-05","article-title":"Phosphorylation of Jak2 on Ser523 inhibits Jak2-dependent leptin receptor signaling","volume":"26","author":"Ishida-Takahashi","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0185","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1128\/MCB.01591-05","article-title":"Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor","volume":"26","author":"Mazurkiewicz-Munoz","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0190","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1128\/MCB.24.11.4955-4967.2004","article-title":"Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity","volume":"24","author":"Argetsinger","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0195","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1210\/me.2009-0355","article-title":"Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity","volume":"24","author":"Argetsinger","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0200","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nsmb.2099","article-title":"The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling","volume":"18","author":"Ungureanu","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0205","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2016.07.038_bib0210","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.07.038_bib0215","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.07.038_bib0220","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","article-title":"The changing landscape of biosimilars in rheumatology","volume":"75","author":"D\u00f6rner","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2016.07.038_bib0225","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.clindermatol.2015.10.010","article-title":"Atopic dermatitis in the domestic dog","volume":"34","author":"Pucheu-Haston","year":"2016","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0230","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jid.2016.03.015","article-title":"Canine and human atopic dermatitis: two faces of the same host-microbe interaction","volume":"136","author":"Santoro","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0235","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tvjl.2015.09.016","article-title":"An update on the treatment of canine atopic dermatitis","volume":"207","author":"Saridomichelakis","year":"2016","journal-title":"Vet. J."},{"key":"10.1016\/j.phrs.2016.07.038_bib0240","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cpm.2016.02.004","article-title":"Psoriasis: pathogenesis, assessment, and therapeutic update","volume":"33","author":"Schleicher","year":"2016","journal-title":"Clin. Podiatr. Med. Surg."},{"key":"10.1016\/j.phrs.2016.07.038_bib0245","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/1756283X16643242","article-title":"Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis","volume":"9","author":"Sofia","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0250","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2016.07.038_bib0255","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-016-3012-z","article-title":"Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib","author":"Bryan","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0260","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.07.038_bib0265","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.07.038_bib0270","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.2015.62.9337","article-title":"Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease","volume":"34","author":"Geyer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0275","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ajh.21129","article-title":"Prevalence of polycythemia vera and essential thrombocythemia","volume":"83","author":"Ma","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0280","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.phrs.2016.07.038_bib0285","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","article-title":"Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976\u2fff1995","volume":"61","author":"Mesa","year":"1999","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0290","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1403141","article-title":"Two clinical phenotypes in polycythemia vera","volume":"371","author":"Spivak","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.07.038_bib0295","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3324\/haematol.2015.132142","article-title":"JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications","volume":"100","author":"Springuel","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2016.07.038_bib0300","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0305","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL\u00ae) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy","volume":"37","author":"Gonzales","year":"2014","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2016.07.038_bib0310","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1021\/acs.jmedchem.5b00301","article-title":"Discovery of VX-509 (decernotinib): a potent and selective janus kinase 3 inhibitor for the treatment of autoimmune diseases","volume":"58","author":"Farmer","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2016.07.038_bib0315","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2016.07.038_bib0320","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1021\/jm501262q","article-title":"Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634","volume":"57","author":"Menet","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2016.07.038_bib0325","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1038\/bcj.2013.6","article-title":"Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F","volume":"3","author":"Ma","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.phrs.2016.07.038_bib0330","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10822-012-9572-z","article-title":"Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)","volume":"26","author":"Poulsen","year":"2012","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.phrs.2016.07.038_bib0335","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jmb.2010.05.020","article-title":"Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6","volume":"400","author":"Chrencik","year":"2010","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0340","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/vde.12088","article-title":"A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel\u00ae) in client-owned dogs with atopic dermatitis","volume":"24","author":"Cosgrove","year":"2013","journal-title":"Vet. Dermatol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0345","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/vde.12186","article-title":"A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs","volume":"26","author":"Little","year":"2015","journal-title":"Vet. Dermatol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0350","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2016.07.038_bib0355","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2016.07.038_bib0360","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.07.038_bib0365","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0370","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.07.038_bib0375","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.07.038_bib0380","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2016.07.038_bib0385","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/jpet.114.221176","article-title":"VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease","volume":"353","author":"Mahajan","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"April 15","key":"10.1016\/j.phrs.2016.07.038_bib0390","article-title":"Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings","author":"Genovese","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2016.07.038_bib0395","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2016.07.038_bib0400","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic modeling of filgotinib (glpg0634), a selective jak1 inhibitor, in support of phase iib dose selection","volume":"54","author":"Namour","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2016.07.038_bib0405","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2016.07.038_bib0410","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2016.07.038_bib0415","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms","volume":"115","author":"Tyner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.07.038_bib0420","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","article-title":"Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2016.07.038_bib0425","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"115","author":"Santos","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.07.038_bib0430","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2050-7771-1-5","article-title":"Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application","volume":"1","author":"Furqan","year":"2013","journal-title":"Biomark. Res."},{"key":"10.1016\/j.phrs.2016.07.038_bib0435","first-page":"2655","article-title":"Emerging treatment options for myelofibrosis: focus on pacritinib","volume":"9","author":"Chow","year":"2016","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.phrs.2016.07.038_bib0440","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1073\/pnas.94.8.3565","article-title":"Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates","volume":"94","author":"Shah","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.07.038_bib0445","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0968-0896(98)00099-6","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src","volume":"6","author":"Liu","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2016.07.038_bib0450","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2016.07.038_bib0455","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1021\/cb300610s","article-title":"Kinase drug discovery\u2fffwhat's next in the field?","volume":"8","author":"Cohen","year":"2013","journal-title":"ACS Chem. Biol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816307137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816307137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,15]],"date-time":"2018-07-15T01:38:06Z","timestamp":1531618686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816307137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":91,"alternative-id":["S1043661816307137"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.07.038","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.07.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}